Document Detail

Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction a meta-analysis.
MedLine Citation:
PMID:  21492765     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: We sought to determine whether pharmacologic interventions changed exercise capacity, diastolic function, and mortality in a meta-analysis of trials in heart failure with preserved ejection fraction.
BACKGROUND: Treatment strategies for heart failure with preserved ejection fraction remain unproven despite several large-scale trials.
METHODS: Trials were included in the systematic review where clear comparisons between trial drug and diuretic or placebo were available. Exercise tolerance was assessed by treadmill time, and changes in diastolic function were quantified by transmitral flow (E/A ratio). The primary outcome was all-cause mortality. Weighted mean differences (MDs) and relative risks (RRs), along with their corresponding 95% confidence intervals (CIs), were computed using random-effects models for continuous and dichotomous variables, respectively. The impact of potential covariates was assessed by meta-regression.
RESULTS: Data from 53,878 patients enrolled in 30 published reports were collated, including 18 randomized controlled trials (n = 11,253) and 12 observational studies (n = 42,625). In the randomized controlled trials, exercise tolerance was improved by combined therapy (n = 183; weighted MD = 51.5; 95% CI: 27.3 to 75.7; p < 0.001), whereas E/A ratio was not (n = 472; weighted MD = -0.01, 95% CI: -0.02 to 0.02; p = 0.54) even after accounting for baseline E/A (p = 0.87). Over a mean follow-up of 18.6 months, all-cause mortality was not improved by therapy in randomized controlled trials (RR: 0.99, 95% CI: 0.92 to 1.06; p = 0.70), despite accounting for baseline ejection fraction (p = 0.72). In observational reports, there was a reduction in all-cause mortality with therapy in the unadjusted analyses (RR: 0.80, 95% CI: 0.66 to 0.97; p = 0.27), but not after adjustment for clinical and demographic data (RR: 0.93, 95% CI: 0.84 to 1.02; p = 0.10).
CONCLUSIONS: Pharmacotherapy of heart failure with preserved ejection fraction demonstrates a quantifiable improvement in exercise tolerance but not mortality.
David J Holland; Dharam J Kumbhani; Salim H Ahmed; Thomas H Marwick
Related Documents :
11488325 - Diesel exhaust enhances airway responsiveness in asthmatic subjects.
22362645 - Changes in neutrophil functions during a 10-month soccer season and their effects on th...
21362525 - Impaired heart rate responses and exercise capacity in heart failure patients with pace...
6150725 - H2-receptor blockade and exercise-induced asthma.
15080225 - Comparison of breathing patterns during exercise in patients with obstructive and restr...
17321135 - Bioelectricity production from wastewater treatment in dual chambered microbial fuel ce...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  57     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1676-86     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
School of Medicine, University of Queensland, Brisbane, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein C...
Next Document:  Community prevalence of ideal cardiovascular health, by the American Heart Association definition, a...